Le Lézard
Classified in: Health
Subject: NPT

Lennox-Gastaut Syndrome (LGS) Foundation Announces Exciting New Research Funded in Time for the 9th Annual Walk 'n' Wheel for LGS Research


SAN DIEGO, April 16, 2024 /PRNewswire/ -- On April 20, 2024, the Lennox-Gastaut Syndrome (LGS) Foundation will mobilize families, friends, and communities around the world to 'Step Towards the Cures, Together' at their 9th Annual Walk 'n' Wheel for LGS Research. Click here to learn how you can get involved.

Lennox-Gastaut Syndrome (LGS) is a rare, severe, life-threatening epilepsy syndrome that develops in children and leads to lifelong disability. About 50,000 people in the United States and 1 million people worldwide have LGS. There are no cures for LGS. Together, we can change this!

"Watching Nyla endure years of relentless seizures and the numerous other battles that come with living with LGS fuels my determination to fight alongside her for improved treatments, resources, and support. Every step forward in raising awareness brings hope not just to her, but to all those affected by this terrible disease. This journey isn't just about making a difference for Nyla; it's about creating a brighter future for everyone impacted by LGS." - Erika, Mom to Nyla, Living with LGS.

All funds raised at this event go directly to the LGS Foundation's Finding the Cures, Together Research Program. This vital program drives cutting-edge research that leads to new therapies and treatments for those devastated by LGS.

A critical part of this Research Program is funding patient-led research by awarding Cure LGS 365 Research Grants. The LGS Foundation recently funded an exciting new research study conducted by Drs. Juliet Knowles and Zach Grinspan of Stanford University School of Medicine and Weill Cornell School of Medicine. The research project will identify risk factors and predict the progression of LGS in young children.

"Dr. Knowles and Dr. Grinspan's work is critical to our mission of finding cures and without the funds raised from our community and the Walk 'n' Wheel, we wouldn't have been able to advance this important work," says Dr. Tracy Dixon-Salazar, Executive Director of the LGS Foundation and mom to a 30-year-old daughter who has LGS. "This disease evolves over time in young children, and we know very little about who is at risk. This research project will help us understand the risk factors that lead to LGS and may eventually allow us to intervene before LGS develops." 

For more information, visit the LGS Foundation's website.

About the LGS Foundation
The Lennox-Gastaut Syndrome (LGS) Foundation is a nonprofit organization dedicated to improving the lives of individuals impacted by LGS. It educates the public about LGS, supports families living with the condition, and drives research to find the cures.

SOURCE Lennox-Gastaut Syndrome (LGS) Foundation


These press releases may also interest you

at 16:20
Acadia Pharmaceuticals Inc. today announced that it has awarded 10 academic scholarships to eligible recipients of the first Rett Sibling Scholarship. The Rett Sibling Scholarship program, sponsored by Acadia, was established in 2023 to recognize...

at 16:15
BD (Becton, Dickinson and Company) , a leading global medical technology company, today announced that it will present at the Bank of America Securities Health Care Conference 2024 on Tuesday, May 14, 2024 at 11:00 am Eastern Time. The live webcast...

at 16:11
Xavier University of Louisiana (Xavier), a leading undergraduate institution in preparing Black students to successfully complete medical school, has announced continued progress with Ochsner Health (Ochsner), the Gulf South's leading academic...

at 16:10
CareDx, Inc. ? The Transplant Companytm focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers ? today announced it will report financial...

at 16:10
biote Corp. ("Biote" or the "Company"), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced it has entered into a definitive settlement agreement...

at 16:05
MorphoSys AG reports results for the first quarter of 2024. "The proposed acquisition by Novartis is advancing steadily, and we continue to anticipate its closure in the first half of 2024. The acceptance period for the acquisition is currently...



News published on and distributed by: